Selected aspects of epidemiology of multiple sclerosis in Poland: a multicenter pilot study
Neurologia i Neurochirurgia Polska · 2025
DOI: 10.5603/pjnns.107231 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Neurologia i Neurochirurgia Polska, 2025. Verfasst von Joanna Tarasiuk und 56 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Medical University of Bialystok, Bialystok, Poland. joanna.tarasiuk@umb.edu.pl. Hauptthemen laut MEDLINE: Multiple Sclerosis.
Abstract (Originalsprache)
INTRODUCTION: Multiple sclerosis (MS) is a progressive disease that, if untreated, leads to significant disability. In recent years, several effective disease-modifying therapies (DMTs) have been approved in the European Union and are now available in Poland. This study aimed to evaluate the selected epidemiological and clinical aspects of Polish individuals with MS and to compare the findings with data collected 15 years ago. MATERIAL AND METHODS: Sociodemographic and clinical data were collected from patients with MS between February and April 2024 using a standardized questionnaire across 19 treatment centers in Poland. RESULTS: The study included 3,165 MS patients (mean age, 42.03 years; female-to-male ratio, 2.2:1). The mean disease duration was 10.6 ± 7.85 years, with symptom onset at 30.66 ± 9.84 years and diagnosis at 32.74 ± 10.22 years. The mean Expanded Disability Status Scale (EDSS) score was 2.58 ± 1.6, with mild disability (EDSS 0-3.5) in 78.35% of patients and moderate-to-severe disability (EDSS ≥ 4.0) in 21.65%. Multiple sclerosis subtypes included relapsing-remitting (RRMS) (86.87%), secondary progressive (SPMS) (7.04%), and primary progressive (PRMS) (6.03%). Relapses occurred in 20.43% of patients within the last year, with an overall annual relapse rate of 1.2 in this group. Monofocal onset of the disease was observed in 87.05% of patients, and multifocal onset in 12.95%. Comorbidities were present in 59.73% of patients. Diagnostic tests included magnetic resonance imaging (MRI) (99.84% of patients), cerebrospinal fluid (CSF) analysis (90.91% of patients), visual evoked potentials (VEP) (32.41% of patients), and optical coherence tomography (OCT) (16.11% of patients). At the time of data collection, 97.09% of patients were receiving DMTs, with the following distribution: dimethyl fumarate (25.91%), ofatumumab (16.44%), ocrelizumab (8.62%), teriflunomide (7.44%), natalizumab (5.80%), interferon beta-1a (5.58%), interferon beta-1b (4.97%), ozanimod (4.69%), siponimod (4.15%), glatiramer acetate (4.05%), fingolimod (3.29%), cladribine (3.20%), ponesimod (1.96%), and other therapies (0.88%). CONCLUSIONS: This study highlights substantial progress in the diagnostic and therapeutic management of MS in Poland over the past 15 years. The widespread implementation of MRI and CSF analysis, alongside significantly improved access to DMTs, has contributed to notably better clinical outcomes. These improvements are reflected in reduced relapse rates, slower disability progression, and a decreased prevalence of secondary progressive MS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Medical University of Bialystok, Bialystok, Poland. joanna.tarasiuk@umb.edu.pl.
- Department of Neurology, Medical University of Bialystok, Bialystok, Poland.
- Department of Clinical Medicine, Faculty of Health Sciences, Medical University of Bialystok, Poland.
- Department of Neurology, Faculty of Medicine, Collegium Medicum, University of Rzeszow, Rzeszow, Poland.
- Institute of Neurological Disorders, Department of Clinical Neuroimmunology, Poznan University of Medical Sciences, Poznan, Poland.
- Institute of Neurological Disorders, Department of Neurochemistry and Neuropathology, Poznan University of Medical Sciences, Poznan, Poland.
Zitieren
APA
Tarasiuk, J., Kapica-Topczewska, K., Czarnowska, A., Chorąży, M., Snarska, K. K., Kochanowicz, J., Bartosik-Psujek, H., Rościszewska-Żukowska, I., Czarnota, J., Kalinowska, A., Kania, K., Ambrosius, W., Siuda, J., Galus, W., Walawska-Hrycek, A., Kaczmarczyk, A., Odzimek-Rajska, M., Dubiński, P., Jamroz-Wiśniewska, A., …, & Kułakowska, A. (2025). Selected aspects of epidemiology of multiple sclerosis in Poland: a multicenter pilot study. Neurologia i Neurochirurgia Polska. https://doi.org/10.5603/pjnns.107231
Vancouver
Tarasiuk J, Kapica-Topczewska K, Czarnowska A, Chorąży M, Snarska KK, Kochanowicz J, et al. Selected aspects of epidemiology of multiple sclerosis in Poland: a multicenter pilot study. Neurologia i Neurochirurgia Polska. 2025. doi:10.5603/pjnns.107231
BibTeX
@article{Tarasiuk2025,
author = {Tarasiuk, Joanna and Kapica-Topczewska, Katarzyna and Czarnowska, Agata and Chorąży, Monika and Snarska, Katarzyna Krystyna and Kochanowicz, Jan and Bartosik-Psujek, Halina and Rościszewska-Żukowska, Iwona and Czarnota, Jolanta and Kalinowska, Alicja and Kania, Karolina and Ambrosius, Wojciech and Siuda, Joanna and Galus, Weronika and Walawska-Hrycek, Anna and Kaczmarczyk, Aleksandra and Odzimek-Rajska, Martyna and Dubiński, Piotr and Jamroz-Wiśniewska, Anna and Rejdak, Konrad and Milewska-Jędrzejczak, Marta and Głąbiński, Andrzej and Domitrz, Izabela and Sochań, Patryk and Bednarczyk, Natalia and Kubicka-Bączyk, Katarzyna and Kwinta, Robert and Adamczyk-Sowa, Monika and Krzystanek, Ewa and Lasek-Bal, Anetta and Maciejowska, Katarzyna and Zaborski, Jacek and Podulka, Aleksandra and Klus, Marek and Dorobek, Małgorzata and Zielińska-Turek, Justyna and Palasik, Witold and Pokryszko-Dragan, Anna and Chojdak-Łukasiewicz, Justyna and Nojszewska, Monika and Podlecka-Piętowska, Aleksandra and Sujkowska, Kinga and Zakrzewska-Pniewska, Beata and Zwiernik, Jacek and Litwin, Anna and Chmielewska, Aleksandra and Kazmierchuk, Ihor and Piwowarska, Magdalena and Szajnoga, Beata and Kliszczak, Natalia and Wiercimok, Sonia and Poziombka-Kaźmierczak, Monika and Zwiernik, Beata and Mycko, Marcin and Siwek, Tomasz and Brola, Waldemar and Kułakowska, Alina},
title = {Selected aspects of epidemiology of multiple sclerosis in Poland: a multicenter pilot study},
journal = {Neurologia i Neurochirurgia Polska},
year = {2025},
doi = {10.5603/pjnns.107231}
}
EUVIMED